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The serological responses to both SARS-CoV-1 and SARS-CoV-2 virus have some
unique characteristics that suggest cross-reactive priming by other human coronaviruses
(hCoVs). The early kinetics and magnitude of these responses are, in some cases,
associated with worse clinical outcomes in SARS and COVID-19. Cross-reactive hCoV
antibody responses have been detected in both SARS and COVID-19 patients. There is
also evidence that pre-existing T cell immunity to common cold coronaviruses can
prime the response to SARS-CoV-2. Studies in non-human primates show that SARS-
CoV-1 S-protein vaccine-induced antibodies are associated with acute lung injury in
macaques challenged with SARS-CoV-1. Here we discuss the potential of cross-reactive
immunity to drive the immunopathogenesis of COVID-19 and its implications for current
efforts to develop immune-based therapies and vaccines.
Keywords: COVID-19, SARS-CoV-2, antibody-dependent enhancement, immunopathogenesis, cross-reactivity,
human coronavirusesINTRODUCTION
The new SARS-CoV-2 pandemic has overwhelmed the world with its high contagiousness and
range of severity, presenting from asymptomatic infection or mild symptoms to severe acute
respiratory syndrome with severe morbidity and mortality. The lack of pre-existing immunity is
thought to be one reason for the rampant spread of the virus.
The duration and nature of immune responses to SARS-CoV-2 infection are not yet fully
understood. Many public health responses to COVID-19 outbreaks are based on the assumption
that the infection will result in a protective immune response of undefined duration. However,
correlates of immunity to SARS-CoV-2 may be complicated by the existence of a pre-existing
immunological memory to other human coronaviruses. In addition to SARS-CoV-2, six human
coronaviruses (hCoVs) are known: four seasonal coronaviruses (hCoV-229E, -NL63, -HKU1, and
-OC43) which cause mild upper respiratory diseases, and the two most recently discovered viruses,
SARS-CoV-1 and MERS-CoV, originating from recent zoonotic events. It is generally assumed that
humans are immunologically naive against SARS-CoV-2 and would show a primary immune
response to the infection; however, this could be an oversimplification. The possibility that endemic
coronaviruses may influence the dynamics of SARS-CoV-2 infection in a way seen among other
endemic infections and emerging new variants or viruses should be considered (1, 2).org October 2020 | Volume 11 | Article 5677101
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particular epitopes may prime beneficial protective responses,
and on the other hand, they may prime immunopathology through
mechanisms such as antibody-dependent enhancement (ADE) of
infection, whereby immune complexed virus may be taken up into
cells that lack the ACE2 receptor as shown for other hCoVs at least
in vitro (3, 4).
In the cases of SARS-CoV-1 and MERS, experimental vaccine-
induced antibodies have been associated with an exacerbated
induction of inflammatory cytokines, which is one of the main
clinical features in severe COVID-19 patients (5, 6). The picture is
further complicated by the intrinsic features of SARS-CoV-2.
Blanco Melo et al. (7) compared the host transcriptional response
to SARS-CoV-2 with other respiratory virus infections to identify
signatures that may be underlying the biology of COVID-19. They
demonstrated induction of an aberrant overall transcriptional
response to SARS-CoV-2 where, despite virus replication, the host
fails to launch a robust IFN-I and -III response while concurrently
inducing high levels of chemokines required to recruit effector cells.
It is therefore of paramount importance to understand to what
extent, if any, the adaptive immune response to SARS-CoV-2 can
contribute to virus-induced immunopathogenesis. In this paper we
consider the available evidence on the role of cross-reactive
immunity in the induction of COVID-19 immunopathogenesis,
and we discuss the implications for current efforts to develop
immune-based therapies and vaccines.UNCONVENTIONAL ANTIBODY
RESPONSES ASSOCIATED WITH
DISEASE SEVERITY IN COVID-19, SARS
AND MERS PATIENTS
Canonical antibody responses to novel microbial antigens are
characterized by the early appearance of IgM followed by IgG
and IgA antibodies with an isotype switch pattern typical of a
primary infection. In the case of SARS-CoV-2 infection, IgG
specific for the receptor-binding domain (RBD) of the S1 subunit
of the Spike protein can effectively neutralize viral entry into cells
expressing ACE2 resulting in the control of viral replication in
vitro and in animal models of disease. Rapid and potent virus
neutralizing antibody response should therefore be associated
with viral clearance and disease control.
In contrast to this expectation, several studies on the early
serological response to SARS-CoV-2 have revealed unconventional
patterns of seroconversion similar to those of secondary immune
responses and an unexpected association between early and potent
antibody responses and disease severity. This seroconversion pattern
is suggestive of the presence of some degree of cross-reactive
immunity that could be induced by previous encounters with
common human coronaviruses.
An unconventional pattern of seroconversion to SARS-CoV-2
infection was revealed by the first large serological investigation
of COVID-19 patients reported by Long et al. (8) which showed
three types of seroconversions: IgM before IgG, synchronousFrontiers in Immunology | www.frontiersin.org 2IgM and IgG, and IgM after IgG seroconversion. Most patients
showed the last two patterns. Also noteworthy was the finding
that patients with severe condition had higher IgG and IgM titers
than patients with non-serious conditions.
Similar results were reported by Tan and coauthors (9) who
showed that while IgM antibodies appeared simultaneously to
IgG in severe and non-severe cases, IgG appeared earlier in
severe cases. An earlier IgG seroconversion pattern was also
reported by Pan et al. (10). In a study that assessed the antibody
response to the RBD of the SARS-CoV-2 S1 subunit, Suthar et al.
(11) found that a majority of COVID-19 patients developed
class-switched IgG responses specific for RBD, and also IgM and
IgA titers lower than IgG indicating that antibody class-
switching to IgG occurs early during acute infection. Tan et al.
(9) reported that IgM and IgG responses appear earlier and with
higher titers in severe patients than in non-severe patients while
a significantly higher viral clearance rate was more frequent in
weak than in strong responders. A stronger antibody response
was associated with delayed viral clearance and increased disease
severity in three additional independent studies (9, 12, 13).
Similar observations were also reported following SARS and
MERS infections. Zhang et al. (14) described in patients with
SARS-CoV-1 that the production of virus-neutralizing
antibodies (nAb) in the fatal cases was surprisingly faster than
in recovered cases and reached the highest levels on the 15th day
after the onset of symptoms, while nAb levels in recovered
patients were still increasing. Peak nAb activities were reached
within 20 days in recovered patients compared to 14.7 days in
patients who subsequently died.
Another study by Ho et al. (15) reported that SARS-CoV-1
early serological responders (antibody detectable within 2 weeks)
had a higher mortality rate (29.6 vs. 7.8%) and were more likely
to be over 60 years old. The authors also reported that the disease
was more likely to be of short duration in RT-PCR positive but
seronegative patients. In SARS-CoV-1 patients, at week 2,
consistent clinical progression, shifting radiological infiltrates,
and reversed viral-load profile were associated with disease
worsening, which did not correlate with uncontrolled viral
replication but rather with immunopathological damage (16).
In MERS cases, Ko et al. (17) reported that disease severity was
correlated with both seroconversion rate and peak antibody
levels, while Okba et al. (18) reported a strong response to severe
infections compared to limited or absence of seroconversion in
asymptomatic and mild cases.
There is also evidence of an early IgA response associated
with disease severity. Using an RBD specific IgA, IgG and IgM
test, Huan Ma et al. (19) reported that 4–10 days after symptom
onset, the IgA test exhibited the highest positive diagnostic rate.
Yu et al. (20) reported IgA seroconversion at day 2 after the
symptoms onset, while IgM and IgG appeared at day 5 and the
relative levels of IgA and IgG were significantly higher in severe
patients compared to non-severe patients.
Cervia et al. (12) reported that patients with severe COVID-
19 had a highly significant increase in SARS-CoV-2-specific IgA
and IgG serum titers depending on the duration of symptom
onset, and regardless of patient age and comorbidities. Very highOctober 2020 | Volume 11 | Article 567710
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severe acute respiratory distress syndrome (ARDS).
The apparently early serum IgA response to SARS-CoV-2 is
particularly puzzling as in primary encounter with a new antigen
an IgM response would be expected to appear first. These
preliminary reports should be interpreted cautiously however,
as IgM assays can be insensitive and are frequently configured to
avoid aberrant cross-reactivity due to the polymeric nature of
IgM. It is also possible that total serum IgA levels may be raised
in COVID-19, a possibility that requires further investigation. It
would be informative to study serum for the presence of
multimeric IgA that is normally detectable at only low levels
but which could in principal be elevated in COVID-19 due to
mucosal damage.
The caveats above notwithstanding, taken together, these
early reports provide evidence of an early antibody response
associated with disease severity and the possibility of a priming
effect due to a previous non-SARS-CoV-2 infection.HUMAN CORONAVIRUS
CROSS-REACTIVE ANTIBODY RESPONSES
IN SARS AND COVID-19 PATIENTS
In SARS-CoV-1 the reasons why some patients mount an
antibody response faster than others are still unknown. The
correlation between advanced age and early response with higher
titers is indicative of a priming effect from existing endemic
strains (15). Similarly, higher plasma nAb titers and spike-
binding antibodies have also been observed in elderly and
middle-age patients affected by COVID-19 (21). An increase in
preexisting IgG antibody titers for human coronaviruses OC43,
229E, and NL63 was observed in SARS patients. In addition,
SARS patients without prior exposure to SARS CoV-1, who had
OC43 and 229E infections, showed an increase in antibody titers
specific to the previously encountered hCoV but not to SARS
CoV-1 (22). Acute/convalescent paired samples of SARS patients
displayed a more than 4-fold increase in antibodies to hCoV-
229E, -NL63, and/or -OC43 (23).
Guo et al. (24) tested the reactivities of human plasma
positive for antibodies against NL63, 229E, OC43, HKU1, and
SARS-CoV-1, on a recombinant SARS-CoV-2 nucleoprotein
(rNP) and found no cross-reactivity. A strong cross-reactivity
against SARS-CoV-2 rNP was observed using SARS-CoV-1
positive human plasma (25). However, the consequences of
anti-SARS-CoV-1 antibody cross-reactivity in SARS-CoV-2
patients are probably negligible given the very low prevalence
of SARS-CoV-1 infection.
Evidence of SARS-CoV-2 and HCoV cross-reactive antibody
responses were reported by Nguyen-Contant et al. (26) who
studied two cohorts of SARS-CoV-2 unexposed subjects and a
cohort of COVID-19 convalescent patients. In unexposed
subjects approximately 10% had IgG that bound SARS-CoV-2
S2 but not S1 or the RBD, and 4% had IgG against the SARS-
CoV-2 nucleocapsid (N) protein, which is highly conserved
among coronaviruses. The levels of IgG against S, RBD, S2,Frontiers in Immunology | www.frontiersin.org 3and N were markedly higher in convalescent subjects than
unexposed subjects, indicating strong induction of these Abs
by SARS CoV-2 infection. In convalescent patients, titers of IgG
were higher against the S protein of the HCoV OC43 but not
229E, suggesting a more relevant serological cross-reactivity
between betacoronaviruses. Unexposed subjects exhibited
memory B cell (MBC) reactive to the S proteins of OC43 and
229E. MBCs reactive to SARS-CoV-2 S, RBD, and N were not
found, indicating a very low frequency of these cells in
unexposed subjects. In contrast. the vast majority of COVID-
19 convalescent subjects had circulating IgG MBCs reactive to
the SARS-CoV-2 S1, RBD, and S2 suggestive of a strong
induction by SARS-CoV-2 infection of MBCs reactive to both
novel and conserved regions of the S protein. The authors
suggested that concurrent early production of virus-specific
IgM and IgG in response to SARS-CoV-2 infection might be
mediated by the stimulation of both IgG MBCs as well as naïve B
cells (8, 27–29).
Further substantial evidence of the role played by a cross-
reactive antibody response against hCoVs came recently from a
study by Yonger et al. (30) in a cohort of SARS-CoV-2 infected
children who had multisystem inflammatory syndrome (MIS-C)
and showed broadly elevated IgG responses to other coronaviruses.
More recently, the results of an exhaustive profiling of SARS-
CoV-2 humoral responses in a cohort of 22 patients reported by
Atyeo et al. (31) indicated a skewing of the antibody response to
the N protein in patients who subsequently died and a reciprocal
skewing toward S in patients who survived. Similar findings were
reported by Sun et al. (29). Since both S and N show some degree
of homology among coronaviruses, with N being the most
conserved, identifying the potential cross-reactivity of S and N
antibody responses can help clarify their immunopathogenic role.
An additional feature of the antibody response to SARS-CoV-2
is the rapid recruitment of B cells expressing a limited subset of V
genes, together with extensive activation of IgG and IgA subclasses
without significant somatic mutations (32).
Therefore, early antibody responses to SARS-CoV-2 can be
sustained by both memory B cells primed by previous hCoVs and
naïve B cells rapidly recruited from exposure to SARS-CoV-2, and
the net result of the balance between the two responses may
influence the clinical outcome of the infection.
Gorse et al. (33) observed that functional neutralizing
antibodies are not stimulated as frequently as binding
antibodies. Lv et al. (34) showed that although cross-reactivity
in antibody binding to the spike protein is frequently observed,
viral cross-neutralization is uncommon, which is suggestive of a
non-neutralizing antibody response to conserved S epitopes with
the potential to induce antibody-dependent enhancement.ANTIBODY-DEPENDENT ENHANCEMENT
AND IMMUNOPATHOGENESIS
SARS-CoV-1 antibody-dependent enhancement (ADE) of
infection was first identified by Yang et al. (35) and was
hypothesized to be the reason for such a high mortality rate inOctober 2020 | Volume 11 | Article 567710
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coronaviruses known to cause mild infections such as 229E.
ADE is a mechanism by which Dengue viruses exploit humoral
antiviral immune responses to infect the host’s cells. ADE has also
been well documented in cats infected with the Feline Infectious
Peritonitis Coronavirus (36–38), in which disease severity is
increased following previous immunization against this virus.
Wang et al. (4) found that antisera against SARS-CoV-1
neutralized SARS-CoV-1 infection at high concentrations,
whereas highly diluted antisera significantly increased infection
and induced higher apoptosis levels. SARS-CoV-1 ADE was
found to be primarily mediated by diluted spike-specific
antibodies rather than nucleocapsid specific antibodies.
In the same study, sera from patients that subsequently died
induced a strong increase in IL-8 and MCP-1 by in vitro polarized
monocyte-derived macrophages. In contrast, sera from recovered
patients had no effect on cytokine production, suggesting that the
two patient groups may present different antibody populations.
In experiments conducted using primary human macrophages,
Yip et al. (39) evaluated the effects of anti-Spike antibodies on
susceptibility to SARS-CoV-1 infection. Anti-Spike antibodies
increased the infection of monocyte-derived macrophages by
replication-competent SARS-CoV-1, as well as Spike-
pseudotyped lentiviral particles (SARS-CoVpp). However, ADE-
induced macrophage infection did not support productive viral
replication. In addition, purified anti-Spike IgGs were sufficient to
enhance infection, but not other soluble factors present in the
mouse immune sera, providing strong evidence that IgG-mediated
ADE can cause infection of human macrophages by SARS-CoV-1.
Similar results were reported by Iwasaki and Yang (40) who
showed that the internalization of virus–antibody immune
complexes promotes inflammatory processes and tissue lesions
by activating myeloid cells via FcRs. The virus introduced into
endosomes through this mode will activate the RNA-sensing Toll-
like receptors (TLRs) TLR3, TLR7, and TLR8.
Of particular concern for ADE induction is a mutation in the
RBD of SARS-CoV-2 S1 subunit (D614G) which was recently
reported by Korber et al. (41). The mutation, which is now the
prevalent pandemic form in many countries, may have
originated either in China or Europe and has spread very
rapidly in Europe and the rest of the world. The authors
suggested two possible effects of this mutation on the viral
phenotype: (a) a reduction of S1–S2 subunit interaction,
resulting in increased shedding of S1 from viral-membrane-
bound S2 and (b) a potential induction of ADE: the D614G
mutation is located deep within an immunodominant linear
epitope of the SARS-CoV-1 Spike (S597–603). This peptide has
been recognized as a major immunodominant epitope of SARS-
CoV-1 by analyzing sera from convalescent patients infected
during the 2001 outbreak. The S597-603 peptide reached 64%
serological reactivity and induced long term B-cell memory
responses. In rhesus macaques, S597-603 specific antibodies
mediate both in vitro and in vivo antibody-dependent
enhancement of SARS-CoV-1 infection through an epitope-
sequence dependent mechanism (4). More importantly, the
ADE target peptide embraces the SARS-CoV-2 D614 site andFrontiers in Immunology | www.frontiersin.org 4is identical to the corresponding region in SARS-CoV-1. As
noted by Wang et al. this epitope is located near the RBD, and
antibody binding can mediate a conformational change in Spike
that enhances the interaction between RBD and ACE2 inducing
the enhancement effect.
Antibodies may induce immunopathology also through
mechanisms other than ADE. For example, it has long been
known that IgG antibodies to respiratory syncytial virus (RSV),
detectable in nasopharyngeal aspirates of infants hospitalized
with RSV-induced disease, can trigger antibody-dependent cell-
mediated cytotoxicity (ADCC) (42). Although traditionally, such
antibodies have been considered as a useful clearance mechanism
for virus infected cells it could also be argued that they may have
a damaging role. Hypothetically, shed viral glycoproteins could
bind to uninfected cells through specific and even non-specific
interaction thus making these cells targets for NK cell-mediated
lysis following the binding of specific IgG. The balance between
virus-infectivity neutralizing antibodies and ADCC antibodies
may therefore be critical in determining the clinical outcome. It
has also been suggested that immune complexes formed by non-
neutralizing antibodies bound to viral protein may deposit in
lung capillaries and cause complement activation and tissue
damage, known as antibody-mediated enhanced respiratory
disease (ERD) (43, 44). The potential role of the complement
system also requires investigating particularly given its linkage to
the coagulation pathways.
Serum IgA may also contribute to immunopathology as
suggested by its association with disease severity (12, 19, 20).
sIgA are able to induce interleukin (IL)-6, IL-8, monocyte
chemoattractant protein (MCP)-1 and granulocyte–macrophage
colony stimulating factor (GM-CSF) production by normal
human lung fibroblasts (45). On the other hand, serum IgA can
also mediate anti-inflammatory effects in innate immune cells
(46). In serum, IgA exist in two different molecular forms, namely
monomeric IgA and polymeric IgA. Both forms exhibit
interactions with FcgRI/CD89 to some extent. CD89 is an
activating, g-chain associated, Fc receptor for IgA expressed
on myeloid cells. CD89 induce phagocytosis of complexed
IgA antigens and initiates ADCC (47). Oortwijn et al. (48)
demonstrated that the initial interaction of monomeric and
polymeric IgA with CD89 is similar. However, monomeric IgA
dissociates more rapidly from CD89. In view of the large excess of
monomeric IgA in serum, monomeric IgA competes for CD89
interaction with polymeric IgA, thus preventing cell activation
initiated by receptor aggregation contributing to anti-
inflammatory signals. It may therefore be of interest to
investigate, in COVID-19 patients, the association of these two
different IgA forms with different clinical outcomes.hCoV CROSS-REACTIVE T CELL
MEMORY
There is now also evidence that pre-existing T cell immunity to
common cold coronaviruses can prime the response to SARS-
CoV-2. Using functional validation of predicted epitopes whenOctober 2020 | Volume 11 | Article 567710
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convalescing COVID-19 cases, Grifoni et al. (49) recently
reported that all patients studied consistently generated a
substantial CD4+/CD8+ T cell response against SARS-CoV-2.
In terms of total CD4+ T cell response per donor, on average
~50% of the detected response was directed against the Spike
protein, and ~50% was directed against the rest of the SARS-
CoV-2 ORFeome. More importantly, when the exact same set of
experimental techniques were used with blood samples from
healthy control donors (collected between 2015 and 2018)
substantial cross-reactive coronavirus T cell memory was
detected, suggesting cross-reactive T cell recognition between
seasonal cold coronaviruses and SARS-CoV-2. All healthy
donors were IgG seropositive to HCoV-OC43 and NL63 RBD,
to varying degrees, in line with the endemic nature of these
viruses (50–54).LESSONS FROM VACCINE STUDIES IN
NON-HUMAN PRIMATES
The role of neutralizing antibodies induced by SARS and MERS
CoVs S glycoproteins in protection against viral replication in
susceptible hosts, including mice, ferrets, hamsters, and
macaques (55–57) has been demonstrated in several studies.
However, the effect of Spike-specific immunity in protecting
against lung injury mediated by immunopathological mechanisms
is controversial. Cases of vaccine-induced immunity that
help viral clearance and protect mice or ferrets against lethal
challenge have been reported (58, 59). On the other hand,
in African green monkeys the specific immune memory of
SARS-CoV-1 induced by previous infection enhanced lung
inflammation following a homologous challenge (60). Using
Chinese rhesus macaques, Liu et al. (61) showed the protection
of macaques against viral replication by an MVA-based vaccine.
However, the same animals showed a concomitant enhancement
of acute diffuse alveolar damage suggesting that S-specific
immunity promotes Acute Lung Injury (ALI). In addition, in
productively infected lungs, anti-Spike IgG caused severe ALI by
abrogating a wound-healing macrophage response and TGF-ß
production while promoting the production of proinflammatory
cytokines IL-8 and MCP1 followed by the accumulation of
inflammatory macrophages (6). SARS-CoV-1 infection of
Chinese macaques is generally characterized by prompt control
of viral replication and appearance of mild lung lesions
(61). The mechanisms underlying the resistance of Chinese
macaques to SARS-CoVs-induced ALI are largely unknown.
Liu and colleagues (6) suggest that these effects may be the
consequence of a rapid control of viral replication in the lungs,
sufficient to create a delay between lung inflammation and high-
titer antibody production. Conversely, control of virus
replication may be less efficient in SARS patients since the
peak in viral load coincides with the first appearance of the
antibody response, approximately 10 days after the onset of
symptoms (16). Consistent with these conclusions, previous
administration of anti-S-IgG in Chinese macaques leads toFrontiers in Immunology | www.frontiersin.org 5acute lung injury due to a massive accumulation of monocytes/
macrophages in the lungs (6).DISCUSSION
Based on the available data on COVID-19 patients and data from
the previous SARS-CoV-1 and MERS outbreaks, there is
substantial evidence that cross-reactive B and T cell responses
may establish an unfavorable environment for the primary
immune response to SARS-CoV-2 virus. We have summarized
here increasingly available evidence that supports this
hypothesis, including several reports of unconventional and
accelerated antibody responses associated with disease severity
in COVID-19, SARS, and MERS patients (15, 22–24) as well as
evidence of hCoV cross-reactive antibody responses in SARS and
COVID-19 (24–26, 33, 34). Additional evidence (32) highlights
that human antibody responses to SARS-CoV-2 and other
spillover CoV share similar modalities and are both
characterized by a unique skewing of the B cell repertoire with
an early recruitment of B cells expressing a limited subset of V
genes without significant somatic mutations.
There is also evidence that pre-existing T cell immunity to
common cold coronaviruses can prime the response to SARS-
CoV-2 and that this priming is skewed to spike (49).
It remains to be determined whether immune cross-reactivity
can trigger immunopathogenesis in COVID-19 patients (Figure
1). However, there is sufficient evidence for an antibody
enhancement role in both SARS-CoV and MERS-CoV
infections. Furthermore, in studies on atypical measles and
dengue hemorrhagic fever, as well as in several respiratory
diseases, including RSV and pandemic influenza, the
worsening of the disease following vaccination has been
reported (62, 63).
The observation of Liu et al. (6) on the association of an early
antibody response occurring prior to viral clearance with
abrogated wound-healing responses and increased inflammatory
macrophage-infiltration into the lungs of Chinese rhesus
macaques may be instrumental in understanding the potential
role of an accelerated cross-reactive immunity in the
pathogenesis of COVID-19. Within this framework, cross-
reactivity priming with common hCoVs, sustained by long-
lasting T cell immunity (49) may be responsible for the
unconventional antibody responses observed in COVID-19
patients, with IgG appearing sooner than IgM in severe cases.
Antibody enhancement may play a role in this context,
exacerbating the inflammatory response generated by virus
internalization in macrophages mediated by Fcg Receptors
(FcgR) and/or by other mechanisms.
Tetro (64) suggested that a biological mechanism underlying
the geographical differences in COVID-19 pathogenesis may be
linked to individuals primed by one or more previous exposures
to coronaviruses, and due to the heterogeneity of the antigenic
epitopes, may experience the effects of ADE.
Disease augmentation by previous exposure to seasonal cold
coronaviruses may also partially explain the drop in the case fatalityOctober 2020 | Volume 11 | Article 567710
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the end of March (https://www.epicentro.iss.it/coronavirus/).
The low incidence of COVID-19 in children seems to
contradict the hypothesis of immunopathogenesis requiring
priming with hCoVs, since hCoV infections are common in
children (65). However, the different susceptibility of children to
SARS-CoV-2 morbidity may be due to differences in
composition and functional responsiveness of their immune
system (66). The presence of natural antibodies (67), which are
produced by innate memory B cells, a cell population that is
generated independently of the germinal centers and is most
abundant in children, may contain the infection during the 2
weeks necessary for the production of high-affinity antibodies.
The milder disease in children might also be related to “trained
immunity” (68) which represents an innate immune “memory”
response (69). Another contributing difference may be the lower
expression of the ACE2 receptor of SARS-CoV-2 in children
(70). On the other hand, the finding that SARS-CoV-2 infected
children with a multisystem inflammatory syndrome (MIS-C)
have a dysregulated humoral immune response characterized by
serological reactivity to hCoVs and other respiratory viruses,
provide additional evidence of the immunopathological role of
cross-reactive immunity.
The potential role of early antibody responses in the triggering
of immunopathogenesis has been discounted by several authors
based on the observation that plasma derived from convalescent
patients (both in SARS and COVID-19) has beneficial effects (71–
73). However, the possibility that the early antibody responseFrontiers in Immunology | www.frontiersin.org 6found associated with severe cases versus the late response in
convalescent patients may be sustained by different types of
antibodies should be considered. With the same reasoning, the
selection of convalescent donor plasma based on the titration of
neutralizing antibodies and the timing of treatment should be
carefully considered in the ongoing clinical trials (21).
Finally, the immunopathogenesis potential of cross-reactive
immunity should be considered in current efforts to develop safe
and effective vaccines. Careful selection of antigenic B cell
epitopes will be necessary to avoid the potential induction of
antibody dependent enhancement of disease. In addition,
vaccination strategies that induce airway memory CD4+ T cells
targeting conserved epitopes could be safer and have broader
applicability in the context of COVID-19 and other respiratory
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